PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9725242-9 1998 The down-regulatory effect of IFN-gamma on IL-1beta-induced COX-2 expression was abrogated with cycloheximide. Cycloheximide 96-109 interferon gamma Homo sapiens 30-39 10320641-5 1999 An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX. Cycloheximide 263-276 interferon gamma Homo sapiens 69-78 10320641-5 1999 An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX. Cycloheximide 263-276 interferon gamma Homo sapiens 152-161 10320641-5 1999 An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX. Cycloheximide 263-276 interferon gamma Homo sapiens 152-161 10320641-5 1999 An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX. Cycloheximide 278-281 interferon gamma Homo sapiens 69-78 10320641-5 1999 An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX. Cycloheximide 278-281 interferon gamma Homo sapiens 152-161 10320641-5 1999 An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX. Cycloheximide 278-281 interferon gamma Homo sapiens 152-161 9276525-7 1997 Patients with mild disease showing high inducibility of IFN-gamma mRNA in their PBMC not only had the highest frequency of responders, but also the highest extent of an individual response, defined by superinduction of mRNA, to agents that relieve suppression (gamma-irradiation) or post-transcriptional down-regulation (cycloheximide). Cycloheximide 321-334 interferon gamma Homo sapiens 56-65 9712367-2 1998 The time courses of the inhibition of IFN-gamma-induced kynurenine synthesis by actinomycin D and cycloheximide showed that the indoleamine dioxygenase gene was transcribed as early as 2 h and translated as early as 5 h after initiation of IFN treatment. Cycloheximide 98-111 interferon gamma Homo sapiens 38-47 9754910-4 1998 The ability of IFNgamma to stimulate increased bradykinin receptor expression was abrogated by treatment with either the transcription inhibitor actinomycin D or the protein synthesis inhibitor cycloheximide. Cycloheximide 194-207 interferon gamma Homo sapiens 15-23 9357766-3 1997 L-Thyroxine (T4), 3,5,3"-L-triiodothyronine (T3), and milrinone enhanced the antiviral activity of IFN-gamma up to 100-fold, a potentiation blocked by cycloheximide. Cycloheximide 151-164 interferon gamma Homo sapiens 99-108 9163517-4 1997 A protein synthesis inhibitor, cycloheximide, significantly inhibited cell death, implying that IFN-gamma induces de novo proteins involved in the death of hepatocytes. Cycloheximide 31-44 interferon gamma Homo sapiens 96-105 9130007-8 1997 The LPS and IFN-gamma induced CB increases were abolished by cycloheximide or actinomycin D in the cultures, indicating that the increases in CB required increased RNA transcription and de novo protein synthesis. Cycloheximide 61-74 interferon gamma Homo sapiens 12-21 8624460-5 1996 In this review, a novel posttranscriptional regulation of ICAM-1 gene expression by two inflammatory mediators, interferon-gamma and phorbol myristate acetate, and the possible role of the serine/threonine phosphorylation pathway in the cycloheximide-induced ICAM-1 message stabilization are discussed in light of our current understanding of ICAM-1 gene regulation during an inflammatory response. Cycloheximide 237-250 interferon gamma Homo sapiens 112-128 8910434-6 1996 The induction of IRF-1 mRNA by IFN-gamma in HT-29 cells reaches a maximum at 6 h and is superinduced by cycloheximide. Cycloheximide 104-117 interferon gamma Homo sapiens 31-40 8910434-7 1996 Four mRNA species for BGP are induced by IFN-gamma, the major band of which is inhibited by cycloheximide. Cycloheximide 92-105 interferon gamma Homo sapiens 41-50 8621263-8 1996 Protective effects of IFN-gamma on target cell sensitivity to lysis were blocked by pre-treatment of target cells with actinomycin-D or cycloheximide. Cycloheximide 136-149 interferon gamma Homo sapiens 22-31 7595061-5 1995 Cycloheximide treatment of the cultures containing M-CSF and IFN-gamma inhibited the production of IL-1 beta and TNF-alpha. Cycloheximide 0-13 interferon gamma Homo sapiens 61-70 8680718-9 1995 6 Studies with IL-1 alpha/IFN-gamma combination demonstrated a time dependent expression of iNOS mRNA, first observed at 6 h, peaked at 24 h and was undetectable by 72 h. IL-1 alpha (0.3-10 ng ml-1) and IFN-gamma (10-300 u ml-1) in combination induced a concentration-dependent expression of iNOS mRNA at 24 h. 7 Pretreatment with cycloheximide before IL-1 alpha/IFN-gamma stimulation reduced nitrite levels to basal values. Cycloheximide 331-344 interferon gamma Homo sapiens 26-35 7565811-3 1995 Treatment of U937 with IFN-gamma for 9 hr in the presence of cycloheximide led to super-induction of Fc gamma RI expression. Cycloheximide 61-74 interferon gamma Homo sapiens 23-32 7749068-4 1995 In all these cell lines the level of gamma 2 mRNA increased 2-4 h after induction reaching a stable plateau after 8-12 h. The IFN-gamma induction of gamma 2 mRNA could be blocked by cycloheximide in human amniotic (AMA) cells, epithelial HeLa cells and HT1080 fibroblasts, but not in T98G glioblastoma cells. Cycloheximide 182-195 interferon gamma Homo sapiens 126-135 7814399-3 1995 Northern analysis revealed a dose- and time-dependent suppression of BPAG1 expression by IFN-gamma in cultured human keratinocytes from several different donors, and incubation of the cells with IFN-gamma in the presence of cycloheximide demonstrated that this effect required ongoing protein synthesis. Cycloheximide 224-237 interferon gamma Homo sapiens 195-204 7902828-7 1993 However, treatment with cycloheximide, after stimulation with IFN-gamma, resulted in increased levels of membrane associated ICAM-1. Cycloheximide 24-37 interferon gamma Homo sapiens 62-71 8301141-9 1994 While crg-2 mRNA appeared within 2 h and reached a maximum in 6 to 8 h, Ia mRNA was not detected before 8 h. Cycloheximide superinduced crg-2 mRNA induced by IFN-gamma or UV-NDV but it abolished Ia mRNA induction by the same stimuli. Cycloheximide 109-122 interferon gamma Homo sapiens 158-167 1909216-0 1991 The defective in vitro expression of interferon-gamma messenger RNA in rheumatoid arthritis is recovered by cycloheximide. Cycloheximide 108-121 interferon gamma Homo sapiens 37-53 8502244-5 1993 The addition of cyclohexamide (CX), a protein synthesis inhibitor, to cultures undergoing stimulation with either PMA or IFN-gamma, increased the levels of CD32C mRNA synthesis suggesting that regulatory degradation proteins may be involved. Cycloheximide 31-33 interferon gamma Homo sapiens 121-130 7680009-5 1993 Cycloheximide, which abolished both the IFN gamma- and TNF alpha-induced increases in nitrite production, had no effect on the IFN gamma-induced increase in iNOS mRNA but markedly inhibited the TNF alpha-induced one. Cycloheximide 0-13 interferon gamma Homo sapiens 40-49 8455639-7 1993 Cycloheximide treatment abolished the IFN-gamma induced increase in pIgR mRNA, indicating that induction of pIgR mRNA by IFN-gamma requires de novo protein synthesis. Cycloheximide 0-13 interferon gamma Homo sapiens 38-47 8455639-7 1993 Cycloheximide treatment abolished the IFN-gamma induced increase in pIgR mRNA, indicating that induction of pIgR mRNA by IFN-gamma requires de novo protein synthesis. Cycloheximide 0-13 interferon gamma Homo sapiens 121-130 8425199-6 1993 IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-gamma binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide. Cycloheximide 178-191 interferon gamma Homo sapiens 64-73 8416207-3 1993 In Wish and HEL cells, co-treatment with cycloheximide was required for IFN-gamma to increase the level of RB mRNA. Cycloheximide 41-54 interferon gamma Homo sapiens 72-81 1551894-4 1992 Induction of LAP mRNA is a secondary response to IFN-gamma, blocked by inhibition of protein synthesis with cycloheximide. Cycloheximide 108-121 interferon gamma Homo sapiens 49-58 8355466-6 1993 The synthesis of C4 by PTEC and its regulation by IFN-gamma was fully inhibitable by the addition of cycloheximide, indicating that protein synthesis is required for an increase in C4 secretion. Cycloheximide 101-114 interferon gamma Homo sapiens 50-59 8434236-5 1993 Inhibition with 5,6-dichloro-1-beta-ribofuranosyl-benzimidazole (DRB) indicated a half-life for IFN-gamma-induced SC mRNA of approximately 1 h. Cycloheximide (CHX) abolished the IFN-gamma-induced accumulation of SC mRNA in a reversible manner; the time-course suggested that de novo synthesis of protein factor(s) with a turnover time shorter than 6 h was required for accumulation of SC message. Cycloheximide 144-157 interferon gamma Homo sapiens 96-105 8434236-5 1993 Inhibition with 5,6-dichloro-1-beta-ribofuranosyl-benzimidazole (DRB) indicated a half-life for IFN-gamma-induced SC mRNA of approximately 1 h. Cycloheximide (CHX) abolished the IFN-gamma-induced accumulation of SC mRNA in a reversible manner; the time-course suggested that de novo synthesis of protein factor(s) with a turnover time shorter than 6 h was required for accumulation of SC message. Cycloheximide 159-162 interferon gamma Homo sapiens 96-105 8416207-4 1993 Pre-treatment of THP-1 cells with cycloheximide prior to IFN-gamma treatment augmented the effects of IFN-gamma on RB gene expression. Cycloheximide 34-47 interferon gamma Homo sapiens 102-111 1909216-2 1991 In this study, we have examined the superinduction effect of cycloheximide (CHX) on the IFN-gamma mRNA expression in PHA-stimulated T lymphocytes from nine patients with active RA compared to three healthy individuals. Cycloheximide 61-74 interferon gamma Homo sapiens 88-97 1909216-2 1991 In this study, we have examined the superinduction effect of cycloheximide (CHX) on the IFN-gamma mRNA expression in PHA-stimulated T lymphocytes from nine patients with active RA compared to three healthy individuals. Cycloheximide 76-79 interferon gamma Homo sapiens 88-97 1942774-3 1991 The latter was achieved by analyzing the superinduction of IL-2 and IFN-gamma mRNA occurring upon culture with cycloheximide or after low-dose gamma-irradiation, respectively. Cycloheximide 111-124 interferon gamma Homo sapiens 68-77 1824688-3 1991 The latter was achieved by analyzing, respectively, the superinduction of IL-2 and IFN-gamma mRNA occurring upon culture with cycloheximide or after low-dose gamma-irradiation. Cycloheximide 126-139 interferon gamma Homo sapiens 83-92 1902124-8 1991 Cycloheximide alone is also capable of inducing a rapid increase in class I transcription in both cell types, suggesting that constitutive attenuation of class I transcription may be a common phenomenon, and that IFN-gamma may act, in part, by interfering with such attenuation. Cycloheximide 0-13 interferon gamma Homo sapiens 213-222 1651364-6 1991 The time course of priming by 100 U/ml IFN-gamma showed that at least a 1-h exposure was required, and a maximal effect was seen at 24 h. Priming after a 4-h exposure to 100 U/ml IFN-gamma was completely inhibited by 1 micrograms/ml cycloheximide. Cycloheximide 233-246 interferon gamma Homo sapiens 179-188 1847861-7 1991 However, 0.01-10 micrograms/ml cycloheximide inhibited IFN gamma-induced RT1.B antigen expression in a dose-dependent manner. Cycloheximide 31-44 interferon gamma Homo sapiens 55-64 1824688-7 1991 In cells from trisomic subjects, superinduction of IFN-gamma mRNA by cycloheximide was at least as extensive as for normal donors, while in the case of IL-2 mRNA, it was weaker. Cycloheximide 69-82 interferon gamma Homo sapiens 51-60 2516865-3 1989 Using a combined treatment with cycloheximide and actinomycin D we observed that in HeLa cells IFN-alpha did not need ongoing protein synthesis to induce the enzyme, whereas the addition of cycloheximide prevented the induction by IFN-gamma. Cycloheximide 32-45 interferon gamma Homo sapiens 231-240 35266648-8 2022 Moreover, cycloheximide chase assay showed that degradation of TYR was decreased in IFNG-treated cells. Cycloheximide 10-23 interferon gamma Homo sapiens 84-88 2512344-6 1989 Induction of Leu 13 Ag expression by IFN-gamma was suppressed by cycloheximide. Cycloheximide 65-78 interferon gamma Homo sapiens 37-46 2507660-10 1989 Furthermore, if cycloheximide was added 24 h after IFN-gamma, it actually caused a superinduction of HLA-B transcripts. Cycloheximide 16-29 interferon gamma Homo sapiens 51-60 2107102-5 1990 Addition of inhibitor of protein synthesis, cycloheximide (CHX), at an early stage of induction periods (0-4 h) inhibits the IFN gamma induction by poly I:poly C. Cycloheximide 44-57 interferon gamma Homo sapiens 125-134 2107102-5 1990 Addition of inhibitor of protein synthesis, cycloheximide (CHX), at an early stage of induction periods (0-4 h) inhibits the IFN gamma induction by poly I:poly C. Cycloheximide 59-62 interferon gamma Homo sapiens 125-134 2107102-6 1990 Cell free translation assay using RNAs isolated from NNA cells which are induced by poly I:poly C in the presence of CHX reveals that in these RNAs, IFN gamma mRNA does not exist. Cycloheximide 117-120 interferon gamma Homo sapiens 149-158 2555698-4 1989 Activation by IFN-gamma was slower, sustained, and delayed by cycloheximide. Cycloheximide 62-75 interferon gamma Homo sapiens 14-23 2516865-3 1989 Using a combined treatment with cycloheximide and actinomycin D we observed that in HeLa cells IFN-alpha did not need ongoing protein synthesis to induce the enzyme, whereas the addition of cycloheximide prevented the induction by IFN-gamma. Cycloheximide 190-203 interferon gamma Homo sapiens 231-240 3133656-3 1988 Treatment with the protein synthesis inhibitor, cycloheximide, abolishes the IFN-gamma-induced accumulation of HLA-DR alpha mRNA, indicating that de novo synthesis of a trans-acting protein factor is required for induction of this major histocompatibility complex class II gene. Cycloheximide 48-61 interferon gamma Homo sapiens 77-86 3139787-5 1988 Stimulation of IFN-gamma mRNA by both PMA and IL2 could occur in the presence of cycloheximide, indicating that protein synthesis was not required for the initial stimulation to occur. Cycloheximide 81-94 interferon gamma Homo sapiens 15-24 3133656-6 1988 IFN-gamma-induced transcription of HLA-DR alpha and of the invariant chain gene was blocked by treatment with cycloheximide, but IFN-gamma-induced transcription of HLA-A2 was unaffected. Cycloheximide 110-123 interferon gamma Homo sapiens 0-9 3121611-5 1988 (iii) Cycloheximide (50 micrograms/ml) and anisomycin (10 micron or higher) inhibited the induction by IFN-gamma but not by IFN-alpha 2, suggesting the requirement for some newly synthesized, presumably IFN-gamma-induced, protein factor(s) in IFN-gamma-mediated but not in IFN-alpha 2-mediated induction. Cycloheximide 6-19 interferon gamma Homo sapiens 103-112 2452894-8 1988 When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma. Cycloheximide 70-83 interferon gamma Homo sapiens 41-50 2452894-8 1988 When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma. Cycloheximide 70-83 interferon gamma Homo sapiens 276-285 2452894-8 1988 When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma. Cycloheximide 140-153 interferon gamma Homo sapiens 41-50 2452894-8 1988 When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma. Cycloheximide 140-153 interferon gamma Homo sapiens 276-285 3121611-5 1988 (iii) Cycloheximide (50 micrograms/ml) and anisomycin (10 micron or higher) inhibited the induction by IFN-gamma but not by IFN-alpha 2, suggesting the requirement for some newly synthesized, presumably IFN-gamma-induced, protein factor(s) in IFN-gamma-mediated but not in IFN-alpha 2-mediated induction. Cycloheximide 6-19 interferon gamma Homo sapiens 203-212 3121611-5 1988 (iii) Cycloheximide (50 micrograms/ml) and anisomycin (10 micron or higher) inhibited the induction by IFN-gamma but not by IFN-alpha 2, suggesting the requirement for some newly synthesized, presumably IFN-gamma-induced, protein factor(s) in IFN-gamma-mediated but not in IFN-alpha 2-mediated induction. Cycloheximide 6-19 interferon gamma Homo sapiens 203-212 3121611-6 1988 Interestingly, this inhibition by cycloheximide of the IFN-gamma-mediated induction was overcome by 24 h, whereas a sustained inhibition was obtained with anisomycin. Cycloheximide 34-47 interferon gamma Homo sapiens 55-64 3121611-8 1988 As analyzed by nuclear runoff transcription, IFN-gamma induced the transcription of C5-4-specific RNA within 2 h and it was inhibited by cycloheximide, indicating that the newly synthesized protein mediator(s) required plays a role in the transcriptional activation of the C5-4 gene by IFN-gamma. Cycloheximide 137-150 interferon gamma Homo sapiens 45-54 3121611-8 1988 As analyzed by nuclear runoff transcription, IFN-gamma induced the transcription of C5-4-specific RNA within 2 h and it was inhibited by cycloheximide, indicating that the newly synthesized protein mediator(s) required plays a role in the transcriptional activation of the C5-4 gene by IFN-gamma. Cycloheximide 137-150 interferon gamma Homo sapiens 286-295 3107985-3 1987 gamma-Irradiated cells produce, after exposure to cycloheximide, up to 12-fold greater amounts of IFN-gamma activity. Cycloheximide 50-63 interferon gamma Homo sapiens 98-107 3107985-8 1987 The superinductive effects of cycloheximide and gamma-irradiation on levels of IFN-gamma are additive, suggesting that they affect different aspects of IFN-gamma gene expression. Cycloheximide 30-43 interferon gamma Homo sapiens 79-88 3107985-8 1987 The superinductive effects of cycloheximide and gamma-irradiation on levels of IFN-gamma are additive, suggesting that they affect different aspects of IFN-gamma gene expression. Cycloheximide 30-43 interferon gamma Homo sapiens 152-161 3088147-6 1986 In contrast to IFN-beta 2 mRNA, cycloheximide treatment of lymphocytes produced a slight accumulation of IFN-gamma mRNA. Cycloheximide 32-45 interferon gamma Homo sapiens 105-114 2427623-5 1986 The induction of indoleamine 2,3-dioxygenase by IFN-gamma was inhibited by treatment of the cultures with either actinomycin D or cycloheximide, and thus was dependent on both RNA and protein synthesis. Cycloheximide 130-143 interferon gamma Homo sapiens 48-57 3097508-6 1986 Thus, although little mRNA 561 was synthesized in cells treated either with IFN-gamma alone or with IFN-alpha A and cycloheximide, a large quantity of this mRNA was induced in cells which had been pretreated with IFN-gamma and then treated with IFN-alpha A and cycloheximide. Cycloheximide 261-274 interferon gamma Homo sapiens 213-222 3007500-3 1986 TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma. Cycloheximide 234-247 interferon gamma Homo sapiens 70-79 3007500-3 1986 TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma. Cycloheximide 234-247 interferon gamma Homo sapiens 151-160 3007500-3 1986 TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma. Cycloheximide 234-247 interferon gamma Homo sapiens 151-160 3007500-3 1986 TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma. Cycloheximide 234-247 interferon gamma Homo sapiens 151-160 3081641-6 1986 Cycloheximide inhibits the induction of the invariant chain mRNA by interferon-gamma, suggesting that protein synthesis is required. Cycloheximide 0-13 interferon gamma Homo sapiens 68-84 23975864-11 2013 The IFN-gamma-mediated induction of Trim21 was completely abolished by inhibiting protein synthesis with cycloheximide, and Trim21 expression could not be induced by IFN-gamma in Irf1(-/-) cells, demonstrating that IFN-gamma induces Trim21 indirectly via IRF1 and not directly via STAT1 activation. Cycloheximide 105-118 interferon gamma Homo sapiens 4-13 3935113-3 1985 We show here that in mitogen induced peripheral blood lymphocytes, inhibition of protein synthesis using three different inhibitors (cycloheximide, puromycin, pactamycin) resulted in an increase in the steady-state levels of IFN-gamma mRNA. Cycloheximide 133-146 interferon gamma Homo sapiens 225-234 3155725-10 1985 The turnover of the rIFN-gamma receptor was measured by inhibiting protein synthesis with cycloheximide and the half-life of this receptor was found to be 2 h. The unglycosylated rIFN-gamma was bound to cellular receptors with an affinity similar to that previously reported for natural IFN-gamma. Cycloheximide 90-103 interferon gamma Homo sapiens 21-30 24575118-9 2014 We also demonstrate that IFN-gamma, but not the other stimuli, reduces the proliferation of cycloheximide-primed HK2 cells without affecting their viability. Cycloheximide 92-105 interferon gamma Homo sapiens 25-34 17304101-3 2007 Using the protein synthesis inhibitor cycloheximide and measuring the expression of CD35 in neutrophils stimulated with IFN-gamma and LPS alone or in combination, we could demonstrate that IFN-gamma enhances TLR4 by de novo protein synthesis, whereas the addition of LPS acts synergistically by enhancing vesicular mobilization to the cell surface. Cycloheximide 38-51 interferon gamma Homo sapiens 189-198 19439213-4 2009 The cytoprotective effect of IFN-gamma pretreatment was abolished by the protein synthesis inhibitor cycloheximide. Cycloheximide 101-114 interferon gamma Homo sapiens 29-38 21749909-4 2011 Co-treatment of MM6 cells with IFN-gamma and cycloheximide caused a superinduction of SECTM1 mRNA expression while cycloheximide alone had no effect, illustrating that de novo protein synthesis is not required for IFN-gamma enhanced expression of SECTM1 mRNA, a characteristic of IFN early response genes. Cycloheximide 45-58 interferon gamma Homo sapiens 214-223 21749909-4 2011 Co-treatment of MM6 cells with IFN-gamma and cycloheximide caused a superinduction of SECTM1 mRNA expression while cycloheximide alone had no effect, illustrating that de novo protein synthesis is not required for IFN-gamma enhanced expression of SECTM1 mRNA, a characteristic of IFN early response genes. Cycloheximide 115-128 interferon gamma Homo sapiens 31-40 18678988-8 2008 IFN-gamma did not affect P2X4-receptor mRNA stability, but increased P2X4-receptor gene transcription in a cycloheximide-insensitive manner. Cycloheximide 107-120 interferon gamma Homo sapiens 0-9 15722640-5 2005 We further analyzed the IFN-gamma effect, showing that pretreatment with IFN-gamma strongly suppressed IL-5-induced eosinophil shape change, and cycloheximide (CHX) abrogated the suppression by IFN-gamma, suggesting that new protein synthesis is required for the inhibitory effect by this cytokine. Cycloheximide 160-163 interferon gamma Homo sapiens 24-33 16581346-5 2006 Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect. Cycloheximide 164-177 interferon gamma Homo sapiens 240-249 16581346-5 2006 Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect. Cycloheximide 179-182 interferon gamma Homo sapiens 240-249 15806306-0 2005 IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression. Cycloheximide 109-122 interferon gamma Homo sapiens 0-9 15806306-6 2005 IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis. Cycloheximide 56-69 interferon gamma Homo sapiens 0-9 15806306-6 2005 IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis. Cycloheximide 71-74 interferon gamma Homo sapiens 0-9 11067899-5 2000 The inhibitory effects of IFN-gamma/alpha on the IL-4R mRNA expression require a lag period of about 8 h, and are sensitive to cycloheximide treatment, which suggests that the suppressive effect of IFNs on IL-4R gene expression is a secondary response requiring de novo synthesis of IFN-induced factors. Cycloheximide 127-140 interferon gamma Homo sapiens 26-35 14623896-7 2004 Studies with cycloheximide treatment showed that protein synthesis induced in the first 24 h after IFN-gamma treatment was required for apoptosis under these conditions. Cycloheximide 13-26 interferon gamma Homo sapiens 99-108 14975243-3 2004 In contrast, secretion of other chemokines and interferon-gamma by these cells was sensitive to cycloheximide and detectable only after a lag. Cycloheximide 96-109 interferon gamma Homo sapiens 47-63 12070711-4 2002 Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis. Cycloheximide 0-13 interferon gamma Homo sapiens 131-140 12070711-4 2002 Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis. Cycloheximide 0-13 interferon gamma Homo sapiens 215-224 15220936-6 2004 Cycloheximide inhibited IFNgamma release in such optimal conditions, confirming the ability of PMN to synthesize IFNgamma. Cycloheximide 0-13 interferon gamma Homo sapiens 24-32 15220936-6 2004 Cycloheximide inhibited IFNgamma release in such optimal conditions, confirming the ability of PMN to synthesize IFNgamma. Cycloheximide 0-13 interferon gamma Homo sapiens 113-121 15173890-4 2004 Interestingly, transcription of IFN-gamma but not that of IL-4 was sensitive to cycloheximide treatment, indicating the intrinsic involvement of de novo protein synthesis for IFN-gamma production by NKT cells. Cycloheximide 80-93 interferon gamma Homo sapiens 32-41 15173890-4 2004 Interestingly, transcription of IFN-gamma but not that of IL-4 was sensitive to cycloheximide treatment, indicating the intrinsic involvement of de novo protein synthesis for IFN-gamma production by NKT cells. Cycloheximide 80-93 interferon gamma Homo sapiens 175-184 12505790-3 2003 Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect. Cycloheximide 111-124 interferon gamma Homo sapiens 175-184 11811586-5 2001 However, unlike proliferating cells, no cellular death occurred in the predominantly non-proliferating cells after the treatment of agonistic anti-CD95 antibody with cycloheximide, pretreated with interferon-gamma. Cycloheximide 166-179 interferon gamma Homo sapiens 197-213 10792507-10 2000 The effect of IFN-gamma on RANTES mRNA was reversed by cycloheximide, suggesting that IFN-gamma may act by increasing the rate of translation of RANTES mRNA. Cycloheximide 55-68 interferon gamma Homo sapiens 14-23 10792507-10 2000 The effect of IFN-gamma on RANTES mRNA was reversed by cycloheximide, suggesting that IFN-gamma may act by increasing the rate of translation of RANTES mRNA. Cycloheximide 55-68 interferon gamma Homo sapiens 86-95 10620119-10 2000 Tumor necrosis factor-alpha induced production of C3 and interferon-gamma induced production of factor B were inhibited by cycloheximide. Cycloheximide 123-136 interferon gamma Homo sapiens 57-73 10516755-8 1999 Cycloheximide, but not actinomycin D or brefeldin A, increased CD95-specific cell death only in IFNgamma-treated RS4;11 cells by approximately 12%. Cycloheximide 0-13 interferon gamma Homo sapiens 96-104